Acorda Therapeutics, Inc.

Gargi Roy

Elliott A Gruskin

Jennifer Iaci

Anthony O Caggiano

Andrea M Vecchione

Sarah J Kasperbauer

Rohini D'Souza

Michael P Zimber

Rohini D'souza

Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.

Compositions and methods for promoting neuronal outgrowth

The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system ('CNS') injury or disease.

Proteoglycan degrading mutants for treatment of CNS

This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.

Fusion proteins for the treatment of CNS

Proteoglycan degrading mutants for the treatment of CNS

Growing community of inventors

Boyds, MD, United States of America

Gargi Roy